Avalo Therapeutics, Inc. - Common Stock (AVTX)
7.6600
-0.5600 (-6.81%)
Avalo Therapeutics Inc is a biotechnology company focused on developing and commercializing innovative therapies for rare and devastating diseases
The company utilizes its proprietary drug development platform to identify and advance treatments that target specific biological pathways, aiming to address unmet medical needs in various therapeutic areas. With a commitment to improving patient outcomes, Avalo works on a range of programs that include both preclinical and clinical-stage assets, striving to bring breakthrough solutions to market for patients with limited treatment options.

Via Benzinga · February 28, 2025

Via Benzinga · September 3, 2024

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024

Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions.
Via InvestorPlace · July 24, 2024

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · May 24, 2024

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 13, 2024

Via Benzinga · April 29, 2024

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.
Via Benzinga · April 16, 2024

Via Benzinga · April 9, 2024

Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.
Via Benzinga · April 2, 2024

Via Benzinga · April 2, 2024

Shares of VirTra, Inc. (NASDAQ: VTSI) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter results.
Via Benzinga · April 2, 2024

It's time to check out all of the biggest pre-market stock movers worth watching on with the winners and losers of Tuesday!
Via InvestorPlace · April 2, 2024

Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading
Via Benzinga · April 1, 2024

Via Benzinga · April 1, 2024

It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!
Via InvestorPlace · April 1, 2024

Via Benzinga · March 29, 2024

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 15 points on Thursday. The Dow traded up 0.06% to 39,785.29 while the NASDAQ fell 0.13% to 16,383.85. The S&P 500 also rose, gaining, 0.10% to 5,253.70.
Via Benzinga · March 28, 2024

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share.
Via Benzinga · March 28, 2024

Via Benzinga · March 28, 2024

U.S. stocks traded slightly higher midway through trading, with the S&P 500 gaining around 0.1% on Thursday. The Dow traded up 0.06% to 39,785.87 while the NASDAQ rose 0.06% to 16,408.04. The S&P 500 also rose, gaining, 0.13% to 5,255.09.
Via Benzinga · March 28, 2024

U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corporation (NYSE: REX) rose sharply during Thursday’s session following upbeat quarterly earnings.
Via Benzinga · March 28, 2024

U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell 0.08% to 16,385.80. The S&P 500 also rose, gaining, 0.04% to 5,250.38.
Via Benzinga · March 28, 2024

Avalo Therapeutics shares are soaring after acquiring AVTX-009, a Phase 2-ready anti-IL-1β mAb. With $185 million in gross proceeds, Avalo aims to develop AVTX-009 for hidradenitis suppurativa and other chronic inflammatory indications. Chairman Garry Neil believes AVTX-009 holds immense potential in the multi-billion-dollar HS market.
Via Benzinga · March 28, 2024